Carbomix

Quick links to important sections

Carbomix

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carbomix

Property Description
Active Ingredient Activated charcoal (Activated carbon)
Form Granules for oral suspension (Powder)
Pharmacological Class Intestinal adsorbent, Antidote
General Purpose Gastrointestinal decontamination
Origin Derived (from carbonaceous organic matter)

What Type of Medicine is Carbomix?

Carbomix is a specialized, prescription-only antidote and belongs to the pharmacological class of intestinal adsorbents. This classification is critical for its use in emergency treatment protocols following acute oral toxic ingestions, a role clinically recognized and supported by international toxicological guidelines. Activated charcoal is a foundational agent in the decontamination of patients after oral toxic ingestion. This preparation is a differentiated product often administered under specialized medical supervision to address high-risk poisonings.

Composition and Pharmaceutical Form (Granules for Oral Suspension)

The product is a single-ingredient product composed solely of activated charcoal, chemically termed activated carbon or Carbo activatus. This component is derived from treating carbonaceous organic matter to yield an extremely fine, porous powder with a vast large internal surface area. Carbomix is supplied in the dosage form of granules for oral suspension, a presentation specifically designed for oral administration after being mixed with an aqueous medium. The product has an established use as a non-specific antidote. The fine granularity of this formulation distinguishes it by maximizing the opportunity for the active ingredient to interact rapidly and uniformly with substances throughout the gastrointestinal tract.

How Does Activated Charcoal Function as an Adsorbent?

The central physiological action of Carbomix is adsorption, the physical process of binding and trapping substances onto the charcoal’s surface. This mechanism is crucial because the active ingredient is entirely biologically inert and is not absorbed into the blood from the gastrointestinal lumen. This inertness is a key pharmacological safety feature. By binding to ingested toxins, the charcoal performs gastrointestinal decontamination, achieving the general therapeutic purpose of inhibition of gastrointestinal absorption.

Regulatory References

  1. WHO Essential Medicines List
  2. WHO Essential Medicines List

What side effects are possible with Carbomix?

Possible Side Effects and Safety Information

The safety profile of Carbomix (Activated charcoal) is characterized by its inert, non-absorbed nature, meaning effects are localized primarily within the gastrointestinal tract. Official regulatory documents classify these effects according to frequency and body system.

Documented Adverse Reactions

Classification Adverse Reactions
Common Constipation and the appearance of black stools.
Not Known Vomiting, diarrhoea, and general gastrointestinal obstruction.

Serious Adverse Reactions and Safety Constraints

The most serious documented risks are physical hazards, which are associated with the administration process or specific patient conditions. These risks are categorized under Respiratory and Gastrointestinal disorders:

  • Airway Obstruction: This is a major risk if the charcoal is aspirated (inhaled) into the lungs, especially in patients with impaired consciousness and an unprotected airway. Use is generally contraindicated in this situation.
  • Gastrointestinal Obstruction/Perforation: The serious risks of intestinal blockage (obstruction) or perforation are explicitly associated with multiple-dose activated charcoal therapy and are rare.

Population and Interaction Notes

The regulatory label indicates that the safety of the product has not been established for use during human pregnancy. Furthermore, due to the product’s adsorbent function, there is a documented high-level safety consequence of reduced absorption of any concomitant oral medications, including specific oral antidotes.

Overdose and Emergency Response

The official regulatory profile for Carbomix (Activated Charcoal) overdose is centered on the risks associated with the substance's physical presence and high-dose administration, as the product is not systemically absorbed. Documented overdose manifestations are primarily mechanical, including emesis (vomiting), constipation, abdominal distension, and faecal discolouration (black stools).

The most severe, life-threatening outcomes documented in regulatory warnings are complications affecting the respiratory and gastrointestinal systems. These include pulmonary aspiration leading to aspiration pneumonitis and severe respiratory compromise, as well as the risk of gastrointestinal obstruction or bowel blockage, particularly with repeated high-dose use.

Immediate medical attention must be sought for any suspected overdose event or if severe complications arise. Administration of this product is officially mandated to occur under medical supervision. The official response to these physical complications is symptomatic and supportive treatment, given that no specific antidote is known for the effects of the activated charcoal itself. Airway protection must be ensured before administration in patients with an impaired level of consciousness. Population-specific considerations note that patients with pre-existing motility disorders are at greater risk of obstruction.

Therapeutic Uses of Carbomix

Quick Facts: Carbomix

  • Main Use: Intended for the management of certain types of intoxication, often in emergency situations.
  • Goal: Helps limit the absorption of various substances in the gastrointestinal tract.
  • Function: Works to reduce the systemic exposure to certain ingested chemicals.

Carbomix may be used in the emergency management of select oral poisonings or overdoses. It is intended to help limit the absorption of certain orally ingested toxins within the stomach and intestines. This action may result in a reduction of the amount of the chemical that enters the bloodstream.

The administration of activated charcoal preparations, such as Carbomix, is a common supportive measure in toxicology. Its function is associated with the adsorbent property of charcoal, which can bind to various compounds. This binding helps prevent these substances from being taken up by the body. This approach aims to reduce the risk of systemic effects associated with the absorbed toxin.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Carbomix?

This section outlines the official population eligibility and limitations for Carbomix, based strictly on regulatory prescribing information.

Approved Age Groups and Exclusions

Carbomix is officially approved for use in adults and adolescents (from 12 years of age) and children under 12 years. However, its use is not recommended for neonates (newborn infants). No specific limitations are documented for older adults, who fall under the general adult classification.

Conditional Eligibility and Restrictions

Eligibility is defined by specific conditions for high-risk patients:

  • Unconscious Patients: Administration of Carbomix is conditional and must only occur if a cuffed endotracheal tube is already in place. This strict requirement is mandatory to protect the patient's airway and prevent aspiration.
  • Gastrointestinal Motility: Use requires caution in patients exposed to toxins that are known to interfere with or slow down gastrointestinal motility (e.g., anticholinergics or opioids).

Pregnancy and Lactation Status

The safety of Carbomix use during human pregnancy has not been established through sufficient data. However, because the active ingredient, activated charcoal, is biologically inert and not absorbed into the bloodstream, regulatory authorities state there is no evidence to suggest it should not be used during either pregnancy or lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes the interaction profile for Carbomix, which is dominated by its action as an intestinal adsorbent rather than systemic metabolic activity. As the active ingredient is not absorbed into the bloodstream, interactions occur primarily within the gastrointestinal lumen and are classified as pharmacokinetic (reduced absorption) or pharmacodynamic (additive effect).

Interaction Type Interacting Substance / Category
Exposure Reduction Virtually all orally administered therapeutic medicinal products
Timing Restriction All other oral medicines
Restricted Targets Iron salts, Lithium, Ethanol, Petroleum Distillates, Corrosive Agents
Pharmacodynamic Oral cathartics (laxatives)

The co-administration of Carbomix results in a reduction in the systemic exposure (Cmax and AUC) for nearly all orally administered therapeutic medicines by adsorbing them, which is a pharmacokinetic mechanism. To mitigate this effect, official labeling requires a mandatory separation of administration timing by at least two to three hours from any other oral product. Furthermore, the product’s effectiveness is reduced when administered with food or milk, and it is officially restricted or considered ineffective in poisonings involving substances such as Iron salts, Lithium, and pure Ethanol. Use is also restricted in cases of corrosive agents or petroleum distillates due to lack of efficacy or increased risk, respectively.

Mechanism of Action

How Carbomix Works: Mechanism of Action

Intraluminal Adsorption and Toxin Sequestration

The mechanism of Carbomix is defined by the physical adsorption of a wide range of ingested substances onto the non-biological target of the charcoal’s massive internal surface area. This non-covalent binding interaction, driven by van der Waals forces, sequesters toxins and xenobiotics directly within the gastrointestinal lumen.

Functional Inhibition of Systemic Bioavailability

By physically trapping the substance, the mechanism effectively blocks the Gastrointestinal Absorption Pathway, preventing the toxin's trans-mucosal transport into the bloodstream. This action leads to a direct and profound reduction in the systemic bioavailability, thereby reducing the quantity of substance available to induce systemic effects and the concentration distributed to target organ systems.

Gradient-Driven Elimination and Clearance Modulation

The presence of charcoal maintains a persistent, low concentration of free toxin in the gut, which creates a concentration gradient that can passively draw already-absorbed toxins from the blood back into the lumen (GI dialysis). This process, along with the interruption of enterohepatic recirculation, accelerates the systemic clearance of the substance from the body via subsequent fecal elimination.

Mechanistic Limitations

The adsorption mechanism is strictly lumen-restricted and is functionally irrelevant once the toxin is fully distributed to target organs; the mechanism is time-dependent. Furthermore, the binding is weaker or ineffective against certain highly polar or small molecules, such as inorganic ions, small alcohols, and strong acids or bases.

Dosage and Administration Information

How to Use Carbomix: Official Administration Guidelines

The usage of Carbomix is defined by specific official instructions concerning dosage, preparation, and timing, which restrict its use to a supervised setting for managing acute oral poisonings. The product, supplied as granules, is administered via the oral route after reconstitution or through an intragastric tube.


Dosage and Frequency Regimens

The goal of administration is to give the initial dose as soon as possible after the potential toxin has been ingested. Standard labeled dosage varies significantly by age group:

  • Adults and Adolescents (from 12 years): The standard initial dose is between 50 g and 100 g of activated charcoal.
  • Children (under 12 years): The typical dose is calculated as 1 g per kg body weight, or a fixed dose of 25 g (half a bottle). Use in neonates is not recommended.

In cases of severe poisoning, the initial single dose may be followed by a multiple-dose regimen of 20 g repeated every 4 to 6 hours.


Preparation and Procedural Rules

Carbomix requires specific preparation prior to use. The granules must be beaten loose in the bottle, water must be added up to the designated red mark, and the mixture must be shaken vigorously for 1 minute to form the required suspension. The resultant suspension must be used immediately.

Furthermore, the official instructions recommend administering the suspension with a separation of at least 2 hours from other oral medications to prevent the adsorption of those agents by the charcoal.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has examined this treatment across various chronic pain conditions.


Evidence in Pain Management

Chronic Low Back Pain

Studies on chronic low back pain evaluated changes in pain scores. Research examined the timing of pain score changes during the first week. Research included evaluations of different administration formats.

  • Trial duration: The duration of trials reviewed ranged from 4 to 12 weeks.
  • Primary Outcome: Most studies evaluated the proportion of participants reporting changes in pain intensity that met pre-defined clinical thresholds.
  • Secondary Outcomes: Some studies assessed whether the drug affects patient-reported quality of life.

Fibromyalgia

Research explored whether the drug was associated with changes in pain in fibromyalgia compared to placebo. Evidence from short-term trials (8 to 14 weeks) was reviewed.

  • Dose Response: Studies examined outcomes associated with different dosages, including the highest tolerable dose.
  • Adverse Effects: Research specifically evaluated tolerability by monitoring pre-defined adverse events compared to control groups.

Research on Functional Improvement

Research evaluated outcomes when the drug was used alongside physical therapy. These studies were designed to evaluate functional capacity using standardized scales.

  • Study Population: Trials included participants with chronic pain and limited mobility.
  • Endpoints: The evaluations focused on changes in the distance walked in a 6-minute walk test and scores on the Oswestry Disability Index.

Research on Outcomes and Profiles

Studies tracked and evaluated participant outcomes over periods of 6 to 12 months. Research assessed pharmacokinetic data in specific patient populations, including those with mild kidney issues.

  • Liver Function: Studies included regular monitoring and reporting of liver enzyme levels to evaluate any potential impact.
  • Dependence Risk: Research examined the potential for dependence or withdrawal symptoms upon cessation of the drug.

Key Studies & References Clinical Guideline for the Management of Chronic Non-Cancer Pain (Relevant National Society)

Frequently Asked Questions (FAQ)

Common questions about Carbomix (FAQ)


Q: How quickly does Carbomix start working?

The action of Carbomix begins immediately upon contact with the substance in the digestive tract (the gut). Because the treatment works by physically trapping the substance before it is absorbed, regulatory guidance emphasizes that the initial dose should be administered as soon as possible after ingestion.


Q: Is Carbomix safe to use while pregnant, according to official documents?

Official regulatory documents state that the safety of this medicine has not been established through sufficient data for use during human pregnancy. However, because activated charcoal is not systemically absorbed (it does not enter the bloodstream), authorities may indicate there is no evidence that would preclude its use during pregnancy for treating acute poisoning, if needed.


Q: Can a person with kidney issues use Carbomix?

Carbomix is not designed to treat kidney conditions, as its purpose is to sequester ingested substances within the gastrointestinal tract. Because the active ingredient is not absorbed, official information does not typically list kidney function as a contraindication for its use in acute poisoning. Consultation with a healthcare professional is necessary to address individual situations and potential drug interactions.


Q: Has Carbomix been approved by regulatory bodies in countries like the US or UK?

Carbomix is officially authorized for sale in the UK and European territories, evidenced by a Marketing Authorisation (MA) number and product information published by authorities like the Irish Health Products Regulatory Authority (HPRA). Regulatory status is specific to each country, and the product information reflects the authorization granted by the local health authority.


Q: Is there a maximum number of times someone can use Carbomix?

The regulatory label specifies a standard multiple-dose regimen for severe poisoning cases, where doses may be repeated every few hours. The document does not specify an absolute maximum total number of doses. However, official information notes that risks such as intestinal obstruction increase with prolonged or multiple-dose therapy.


Q: Can Carbomix be mixed with other liquids before use?

Official preparation rules for Carbomix specify that water must be added to the granules to form the suspension. It is important to note that the product's effectiveness is reduced when it is administered with food or milk, so these liquids should not be used for mixing.


Q: Is it normal to feel bloated after using Carbomix?

The official documentation lists constipation as a common side effect, a symptom related to gastrointestinal issues. Bloating or abdominal discomfort may also be noted in patient experiences, though the effects are typically localized to the gastrointestinal tract.


Q: Do official materials describe any risk of overdose with Carbomix?

Official information primarily discusses serious risks associated with the administration process, such as aspiration (inhalation) into the lungs, or risks related to multiple-dose therapy, like intestinal obstruction. The regulatory focus is on minimizing the risks associated with the administration process and prolonged use.


Q: Does Carbomix have a bitter taste?

Activated charcoal, the active ingredient in Carbomix, is commonly described in pharmacopeial and toxicology references as being odourless and tasteless. It is recognized that the product's suspension may take on the taste of the liquid used for preparation.


Q: Are there any official restrictions on driving or operating machinery after using Carbomix?

The official product information states that the section concerning 'Effects on ability to drive and use machines' is considered Not Applicable. This is because the product is used in acute poisoning situations, which would inherently prohibit a patient from driving or operating machinery regardless of the drug's effect.


Q: Do official documents mention any potential for allergic reactions to Carbomix?

While allergic reactions are a possible risk with any medication, official product safety information does not typically list them as a common or known undesirable effect. The appearance of signs of a severe allergic reaction (such as swelling or difficulty breathing) constitutes an urgent medical situation.


Q: What is the shelf life of Carbomix?

Official product labels typically assign a specific shelf life, often ranging from one to three years, to ensure the product maintains its effectiveness. The charcoal’s potency is maintained by adherence to specific storage conditions, including keeping the container tightly closed and protected from moisture.

How should Carbomix be stored and disposed of?

Storage and Disposal Requirements for Carbomix

The storage and disposal of Carbomix (activated charcoal, granules for oral suspension) must strictly follow the conditions defined in the official regulatory label.

Mandatory Storage Conditions

Requirement Specification
Temperature Store below 25 C (77°F).
Moisture Protection Keep the container tightly closed to protect the granules from moisture.
Container Store in the original container.
Child Safety Keep out of the sight and reach of children.

Disposal

There are no explicit instructions for discarding Carbomix in household waste. Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste, as directed by regulatory labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carbomix found in:

A-Z Index: